Introduction
============

The major types of epithelial renal tumors include clear cell (75%), papillary (15%), chromophobe (5%), and oncocytoma (5%). Mutations in the von Hippel Lindau (*VHL*) tumor suppressor gene are associated with hereditary and sporadic forms of clear cell renal carcinoma only. The product of the *VHL* gene forms a heterodimeric complex with elongin C, elongin B, Cul-2, and RBX1 and targets the hypoxic inducible factors (HIF1α and HIF1β) for ubiquitin-mediated degradation. Mutation of the *VHL* gene in clear cell kidney cancer prevents the VHL complex from targeting HIFs for degradation, resulting in their accumulation. Increased levels of HIF result in increased transcription of downstream targets including VEGF and angiogenic pathways (Linehan et al., [@B11]).

Over the last few years, anti-VEGF therapies have made a major impact in the standard of care for patients with advanced clear cell renal cell carcinoma (CCRCC; Patard et al., [@B17]). These include bevacizumab (Yang et al., [@B23]), sunitinib (Motzer et al., [@B13]), axitinib (Rixe et al., [@B18]), pazopanib (Sternberg et al., [@B20]), and sorafenib (Motzer et al., [@B14]).

We had previously reported the possible impact of *VHL* gene mutation and promoter hypermethylation on the outcome to VEGF-targeted agents in patients with advanced CCRCC (Choueiri et al., [@B3]). While the overall response rate (ORR) to VEGF-targeted therapy in patients with metastatic RCC was not correlated with *VHL* inactivation, subset analysis suggested that loss of function VHL mutations may identify patients with increased ORR to VEGF-targeted agents.

Extensive genetic differences between matched primary and metastatic tumors in 6 out of 19 CCRCC cases following comparative genomic hybridization (CGH) analysis (Bissig et al., [@B1]) and intra-tumoral heterogeneity of VHL gene deletions (Moch et al., [@B12]) have been reported. Based on the availability of paired primary and metastatic tumors from 10 patients, the goal of this exploratory study was to determine whether the *VHL* genotype can indeed differ in these paired tissue samples.

Materials and Methods
=====================

DNA sequence analysis
---------------------

Genomic DNA was isolated from formalin fixed paraffin-embedded (FFPE) tumor biopsies as described in Choueiri et al. ([@B3]) after manual micro dissection (Blaveri et al., [@B2]). Samples that were at least 80% tumor, as determined by a pathologist (HA and MZ), were included in the study. A total of seven primer sets were used to amplify overlapping fragments of the coding region of the *VHL* gene (Figure [1](#F1){ref-type="fig"}). Due to inherent problems with quality of DNA extracted from FFPE specimens, three primer sets, two primer sets, and two primer sets were used to amplify exons 1, 2, and 3, respectively. The PCR reactions consisted of 100 ng of genomic DNA, 67 mM Tris-HCL, pH 8.8, 6.7 mM magnesium chloride, 16.6 mM ammonium sulfate, 10 mM 2-mercaptoethanol, 12.5 mM dNTP's, and 10% DMSO, 0.5 μM primers, and 0.25 units of Platinum Taq polymerase (Invitrogen, Carlsbad, CA, USA). The primer sequences used were as follows: Exon 1A--F: 5^′^-CGAAGACTACGGAGGTCGAC-3^′^; 1A--R: 5^′^-TCTTCAGGGCCGTACTCTTCG-3^′^; 1B--F: 5^′^-AGGCCGAGGTAGGCGCGGA-3^′^; 1B--R: 5^′^-GCAGAAGATGACCTGGGAGGGC-3^′^; 1C--F: 5^′^-CTGCGCTCGGTGAACTCG-3^′^; 1C--R: 5^′^-CTATCGTCCCTGCTGGGTCG-3^′^; 2A--F^′^: 5^′^-GGATTACAGGTGTGGGCCAC-3^′^; 2A--R^′^: 5^′^-GGCTGTCCGTCAACATTGAG-3^′^; 2B--F: 5^′^-ACGATGGGCTTCTGGTTAAC-3^′^; 2B--R: 5^′^-CCTGTACTTACCACAACAACC-3^′^; 3A--F: 5^′^-TCCTTGTACTGAGACCCTAG-3^′^; 3A--R: 5^′^-TTTGGGTGGTCTTCCAGATC-3^′^; 3B--F: 5^′^-ATTACAGGAGACTGGACATC-3^′^; 3B--R: 5^′^-CCAGTCCTGTATCTAGATC-3^′^.

![**Schematic of *VHL* gene mutations identified in the patient cohort**. \*Patient ID number. \*\*Overlapping regions amplified by PCR.](fonc-02-00051-g001){#F1}

The amplicons underwent Sanger sequencing using the ABI377 automated sequencer (Applied Biosystems, Foster City, CA, USA) at the Genomic's Core Facility, Lerner Research Institute, Cleveland Clinic. Sequences derived from the amplified samples were compared to the wild-type *VHL* sequence (GenBank Accession No. AF010238) using LaserGene software (DNAStar, Perkin Elmer, Foster City, CA, USA) to identify mutations. A subset of samples was also sent to Transgenomics (Omaha, NE, USA) for independent analysis of the *VHL* genotype. Sequence variations were identified on PCR-amplified samples that were screened using the mismatch cleavage enzyme, Surveyor, and DHPLC/WAVE® analyses followed by sequencing at Transgenomic (Nickerson et al., [@B16]).

Methylation assay
-----------------

Methylation status was determined using *VHL* methylation-specific PCR primers after DNA bisulfite modification. Genomic DNA was modified using the EZ DNA Methylation-Gold Kit according to the manufacturer's protocol (Zymo Research, Orange, CA, USA). The product then underwent PCR-based amplification using methylation-specific primers described previously (Herman et al., [@B8]). Methylation status was determined by gel electrophoresis of the PCR products as described in Herman et al. ([@B8]).

Results and Discussion
======================

Paired primary and metastatic tumors were obtained from 10 patients. VHL genotype analysis in this 10 patient cohort included single biopsies from a single primary and metastatic lesion (5 patients), multiple primary and/or metastatic tumors (5 patients) and adjacent normal tissue (6 patients). Sequencing data was obtained from a total of 42 samples (18 primary tumors, 14 metastatic tumors, and 10 adjacent normal tissues). Due to the intrinsic difficulty in identifying true somatic mutations in tissues with genetic heterogeneity, a subset of 16 samples comprised of 8 primary and 8 metastatic samples were also analyzed by Transgenomic for independent assessment of *VHL* gene mutation status (Table [1](#T1){ref-type="table"}). *VHL* genotype assessment of adjacent normal tissue, as well as evaluation of multiple samples where possible contributed to the validation of our data. Patient cohort included six men and four women. While the primary and metastatic tumors were obtained in most patients during a single surgery, in some patients subsequent surgery involved additional metastatic lesions or primary tumor in the contra lateral kidney (Table [1](#T1){ref-type="table"}, patients 6 and 10).

###### 

**von Hippel Lindau genotype and Fuhrman grade in primary and metastatic CCRCC tumors**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pat. ID                                                                                 Sample ID   Surgery date   Primary (P)/metastatic (M)/normal                                                                     VHL genotype                           Fuhrman grade                  
  --------------------------------------------------------------------------------------- ----------- -------------- ----------------------------------------------------------------------------------------------------- -------------------------------------- --------------- ----- -- -- -- --
  **CATEGORY 1: PATIENTS WITH IDENTICAL PRIMARY AND METASTATIC VHL GENOTYPE IN TUMORS**                                                                                                                                                                                                          

  4                                                                                       1           12/2004        Primary, left kidney (P)                                                                              WT                                     Not evaluated                  

  4                                                                                       2           12/2004        Metastatic, lymph node (M)                                                                            WT                                     Not evaluated                  

  5                                                                                       3           8/2002         Primary, left kidney (P)                                                                              478delG, ex3                           0               100            

  5                                                                                       4           8/2002         Metastatic, lymph node (M)                                                                            478delG,ex3                            0               100            

  5                                                                                       5           8/2002         Adjacent normal                                                                                       WT                                                                    

  8                                                                                       6           2/2005         Primary, right kidney (P)                                                                             Methylated Promoter                    20              80             

  8                                                                                       7           2/2005         Metastatic, adrenal (M)                                                                               Methylated Promoter                    0               100            

  9\*                                                                                     8           8/2003         Primary, left kidney (P)                                                                              232delA,ex1                            10              90             

                                                                                                                     Renal tumor                                                                                                                                                                 

  9                                                                                       9           8/2003         Primary, left kidney (P)                                                                              232delA,ex1                            89              11             

                                                                                                                     Tumor close to capsule                                                                                                                                                      

  9\*                                                                                     10          8/2003         Metastatic, lymph node (M)                                                                            232delA, ex1                           95              5              

  11                                                                                      11          2/2004         Primary, left kidney (P)                                                                              349delT,ex1                            10              90             

  11                                                                                      12          2/2004         Metastatic, small bowel (M)                                                                           349delT,ex1                            50              50             

  11                                                                                      13          2/2004         Adjacent normal                                                                                       WT                                                                    

  13                                                                                      14          3/2004         Primary, right kidney (P)                                                                             WT                                     100             0              

  13                                                                                      15          3/2004         Metastatic, left adrenal (M)                                                                          WT                                     99              1              

  13                                                                                      16          3/2004         Adjacent normal                                                                                       WT                                                                    

  **CATEGORY 2: PATIENTS WITH DIFFERENT PRIMARY AND METASTATIC VHL GENOTYPE IN TUMORS**                                                                                                                                                                                                          

  6\*                                                                                     17          5/2003         Primary, left kidney (P)                                                                              407insATATATAT, ex2                    100             0              

  6\*                                                                                     18          5/2004         Metastatic, fallopian tube (M)                                                                        WT                                     100             0              

  6\*                                                                                     19          5/2004         Metastatic, fallopian tube (M)                                                                        WT                                     100             0              

  6\*                                                                                     20          5/2004         Metastatic fallopian tube (M)                                                                         407insATATATAT, ex2                    100             0              

  6                                                                                       21          5/2003         Adjacent normal                                                                                       WT                                                                    

  7\*                                                                                     22          8/2004         Primary, left kidney (P)                                                                              WT                                     100             0              

  7\*                                                                                     23          8/2004         Metastatic, colon (M)                                                                                 G463C, ex2                             0               100            

  10\*                                                                                    24          9/2002         Primary, right kidney (P)                                                                             WT                                     90              10             

                                                                                                                     Renal vein margin with tumor                                                                                                                                                

  10\*                                                                                    25          9/2002         Primary, right kidney (P)                                                                             C333G, ex1                             10              90             

                                                                                                                     Spatially separated representative section of primary tumor                                                                                                                 

  10\*                                                                                    26          12/2003        Primary, left kidney (P)                                                                              C333G, ex1                             45              55             

                                                                                                                     Representative section of tumor in relation to capsular margin                                                                                                              

  10\*                                                                                    27          12/2003        Primary, left kidney (P)                                                                              C333G, ex1                             66              34             

                                                                                                                     Representative section of tumor in relation to parenchymal margin                                                                                                           

  10\*                                                                                    28          12/2003        Metastatic, lymph node (M)                                                                            C333G, ex1                             100             0              

  10                                                                                      29          9/2002         Adjacent normal                                                                                       WT                                                                    

  10                                                                                      30          12/2003        Adjacent normal                                                                                       WT                                                                    

  10                                                                                      31          12/2003        Adjacent normal                                                                                       WT                                                                    

  12                                                                                      32          3/2004         Primary, right kidney (P)\                                                                            del31 bp, intron 1, 9nt before ex2     95              5              
                                                                                                                     Representative section of closest parenchymal margin including area with renal sinus bulge of tumor                                                                         

  12                                                                                      33          3/2004         Primary, right kidney (P)\                                                                            del31 bp in intron 1, 9nt before ex2   95              5              
                                                                                                                     Representative section of closest parenchymal margin including area with renal sinus bulge of tumor                                                                         

  12                                                                                      34          3/2004         Primary, right kidney (P)\                                                                            del31 bp in intron 1, 9nt before ex2   95              5              
                                                                                                                     Representative section of same primary                                                                                                                                      

  12\*                                                                                    35          4/2004         Primary, left kidney (P)                                                                              WT                                     90              10             

                                                                                                                     Sections of tumor with capsule                                                                                                                                              

  12                                                                                      36          4/2004         Primary, left kidney (P)                                                                              WT                                     50              50             

                                                                                                                     Same primary                                                                                                                                                                

  12\*                                                                                    37          3/2004         Lung metastasis                                                                                       WT                                     10              90             

                                                                                                                     Parenchymal line of resection                                                                                                                                               

  12\*                                                                                    38          3/2004         Lung metastatsis                                                                                      WT                                     10              90             

                                                                                                                     Pleural margin of tumor                                                                                                                                                     

  12                                                                                      39          3/2004         Lung metastasis                                                                                       WT                                     10              90             

                                                                                                                     Remaining metastatic tissue                                                                                                                                                 

  12                                                                                      40          3/2004         Adjacent normal                                                                                       WT                                                                    

  12                                                                                      41          3/2004         Adjacent normal                                                                                       WT                                                                    

  12                                                                                      42          3/2004         Adjacent normal                                                                                       WT                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*All nucleotide positions are numbered with the adenosine of the AUG start site as position number 1. This corresponds to nt position 214 in the mRNA sequence GenBank accession no. NM_000551. DNA sequencing traces are included in Appendix*.

*\*Samples that were also sent to Transgenomic*.

A total of seven patients harbored mutations in the *VHL* gene in the primary and/or metastatic lesions, 1 patient exhibited *VHL* gene methylation, and two patients had the wild-type *VHL* genotype (Table [1](#T1){ref-type="table"}; Figure [1](#F1){ref-type="fig"}). Sequencing traces identifying VHL genotype for data in Table [1](#T1){ref-type="table"} are included as Figure [A1](#FA1){ref-type="fig"} in Appendix. Mutations identified in this study were not observed in our previous larger 123 patient cohort of primary tumors (Choueiri et al., [@B3]) suggesting that mutations were unique to the patient in which it was first described. Further, no two patients had identical *VHL* mutations and methylation in this and our previous study (Choueiri et al., [@B3]) was observed only where the *VHL* genotype was wild-type. The *VHL* gene was methylated in 12 out 123 patients (10%) in the Choueiri study (Choueiri et al., [@B3]). Notably in 4 out of 10 patients the *VHL* genotype differed between the primary and matched metastatic lesion. Also in 2 of these patients, while the primary tumor was wild-type a mutant *VHL* genotype was identified in the paired metastatic lesion (patient \#7 and \#10, Table [1](#T1){ref-type="table"}) likely due to intra-tumor heterogeneity. Inter- and intra-tumor heterogeneity in *VHL* genotype is exemplified in patients 10 and 12 (Table [1](#T1){ref-type="table"}) between the primary tumor in different kidneys as well as metastasis removed at surgery. Additional data supporting heterogeneity in *VHL* genotype is based on identification of wild-type and mutant *VHL* in the primary tumor (patient \#10 and \#12) and in metastasis (patient \#6) when different micro dissected tumor areas were analyzed. *VHL* mutations, when present, were identical between primary and metastatic sites and the *VHL* genotype in adjacent normal tissue in all 6/10 patients analyzed was wild-type, irrespective of *VHL* gene status of tumor tissue. VHL mutation status was not found to correlate with tumor grade (Table [1](#T1){ref-type="table"}).

Polyclonality in colorectal adenomas (Thirwell et al., [@B21]), genetic heterogeneity in tumors with mutations in a single gene (Dalgliesh et al., [@B4]) and genetic diversity based on single cell sequencing (Navin et al., [@B15]) suggests that the focus on specific genetic lesions for personalized targeted therapy may be overly simplistic. More recently (while this manuscript was under review), intra-tumor heterogeneity in RNA expression or inactivating mutations in renal carcinoma has been reported (Gerlinger et al., [@B7]). The present study and previous reports (Moch et al., [@B12]; Bissig et al., [@B1]) emphasize that multiple genetically different clones are possibly present in clear cell renal carcinoma and this could contribute to the observed differences in *VHL* genotype between the primary and metastatic tumor in the same patient. Since the patients in this study had sporadic CCRCC, it is likely that clonal heterogeneity and mutations in the *VHL* gene may occur either during tumor development or subsequent tumor progression. This possibility is supported by the heterogeneity in *VHL* genotype within a single primary (Patient 6) or metastasis (Patient 12) when different spatially separated tumor sites was analyzed for *VHL* genotype. It is also becoming increasingly apparent that several targets for current cancer therapies can also display discordance in expression or mutation status between primary and metastatic sites. Previous studies in breast (Torres et al., [@B22]) and melanoma (Katona et al., [@B10]) cases have reported extensive genetic heterogeneity between primary and metastatic tumors. Detailed assessments of PIK3CA mutations between primary and matched metastatic breast tumors report not only discordance in mutations but also microheterogeneity in mutational status of the primary tumor (Dupont Jensen et al., [@B5]). Similarly, discordance in HER2 expression between primary and paired metastatic breast cancer tumors is reported to occur at a significant rate (Fabi et al., [@B6]; Houssami et al., [@B9]). Even in a CCRCC study of unmatched primary tumors and metastatic lesions, significant differences between primary and metastatic renal tumors in the expression levels of several proteins involved in the mTOR pathway including phos-AKT, phos-S6, 4EBP1, and c-myc were reported (Schultz et al., [@B19]). In summary, these studies suggest marked molecular heterogeneity between primary and metastatic solid tumors.

The *VHL* gene is unique in that somatic mutations are observed only with kidney tumors and the aberrant signaling due to *VHL* mutations has a direct effect on the angiogenic pathway. Although *VHL* is classified as a tumor suppressor, nearly 20% of sporadic CCRCC harbor the wild-type *VHL* genotype. While the observed differences in *VHL* genotype between the primary and metastatic tumor could be ascribed to technical issues, results from the present study were independently validated in 13/16 samples by Transgenomic (Table [A1](#TA1){ref-type="table"} in Appendix) using previously reported methodology (Nickerson et al., [@B16]) and further, the adjacent normal tissue in all cases independent of the tumor *VHL* genotype was wild-type *VHL* since the patients had sporadic CCRCC. In summary, in CCRCC, since primary tumor nephrectomy can precede a subsequent primary in the contralateral kidney and/or metastatic disease, the present results on intra- and inter-tumor heterogeneity in wild-type or mutant VHL gene suggest that reliance on *VHL* genotype of the primary tumor for treatment strategy may not be completely informative.
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###### 

**Comparison of *VHL* genotype calls -- Cleveland Clinic and Transgenomic (*n* = 16 samples)**.

  Patient ID   Sample ID   DNA sequenced at Cleveland Clinic   DNA sequenced and reported by Transgenomic
  ------------ ----------- ----------------------------------- --------------------------------------------
  6P^a^                    407insATATATAT, ex2                 412inATATATAT, ex2
  6M^b^        18          wt                                  wt
  6M           19          wt^c^                               412insATATATAT, ex2
  6M           20          407insATATATAT, ex2                 412insATATATAT, ex2
  7P                       wt^d^                               G463C
  7M                       G463C                               G463C
  9P                       232delA                             232 delA
  9M                       232delA^e^                          P25S, 10% RSI^f^
  10P          24          wt                                  wt
  10P          25          C333G                               C333G
  10P          26          C333G                               C333G
  10P          27          C333G                               C333G
  10M                      C333G                               C333G
  12P                      wt                                  wt
  12M          37          wt                                  wt
  12M          38          wt                                  wt

*^a^Primary*.

*^b^Metastatic*.

*^c,d,e^Calls based on sequence traces presented in Figure [A1](#FA1){ref-type="fig"}*.

*^f^Relative signal intensity (RSI)*.

###### 

**Somatic VHL mutation sequencing in normal and tumor tissue of representative patients from Table [1](#T1){ref-type="table"}**.
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